Reference
Health Canada. LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions. Internet Document : 15 Oct 2019. Available from: URL: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71299a-eng.php
Rights and permissions
About this article
Cite this article
New safety information for alemtuzumab; revised indication. Reactions Weekly 1776, 2 (2019). https://doi.org/10.1007/s40278-019-70160-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-70160-4